Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Abingdon, Oxford : Taylor & Francis
      Original Publication: London : Future Drugs Ltd, [2001-
    • Subject Terms:
      HIV-1*/genetics ; Drugs, Essential* ; HIV Infections*/drug therapy ; HIV Seropositivity*/drug therapy ; Anti-HIV Agents*/adverse effects; Adult ; Humans ; Lamivudine/adverse effects ; Tenofovir/pharmacology ; Tenofovir/therapeutic use ; Cost-Benefit Analysis ; Viral Load ; RNA, Viral/pharmacology ; RNA, Viral/therapeutic use ; Emtricitabine/pharmacology ; Emtricitabine/therapeutic use ; Drug Combinations
    • Abstract:
      Background: In Russia, before 2022, the list of vital and essential drugs for HIV-infected patients previously untreated with antiretroviral drugs included the fixed-dose combination rilpivirine/tenofovir disoproxil fumarate/emtricitabine (RPV/TDF/FTC) but not doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/TDF/3TC).
      Methods: An indirect comparison of the efficacy of DOR/TDF/3TC and RPV/TDF/FTC defined by virologic suppression (HIV-1 RNA of <50 copies/mL at week 48) was made. The per-patient drug costs over 1 year were compared in a cost-minimization analysis. A budget impact analysis considered the costs to the healthcare system of including DOR/TDF/3TC as a treatment option for eligible patients in Russia over a 3-year time horizon.
      Results: The indirect treatment comparison of DOR/TDF/3TC and RPV/TDF/FTC in treatment-naïve patients with baseline HIV-1 RNA 100,000 copies/ml or less showed no statistically significant difference (RR 0.914, 95% CI 0.833-1.003). In the cost-minimization analysis, the per-patient cost of one year of treatment with RPV/TDF/FTC and DOR/TDF/3TC was, respectively, ₽320,975 and ₽151,192, for a saving of ₽169,783. In the budget impact analysis, the adoption of DOR/TDF/3TC into clinical practice is expected to reduce drug costs by ₽333 million (23.8%) in year 3.
      Conclusions: Fixed-dose combination DOR/TDF/3TC is equally effective and cost-saving compared to RPV/TDF/FTC from Russian vital and essential drugs list perspective.
    • Contributed Indexing:
      Keywords: Antiretroviral therapy; HIV infection; doravirine; fixed-dose combination; human immunodeficiency virus; pharmacoeconomic analysis; rilpivirine
    • Accession Number:
      2T8Q726O95 (Lamivudine)
      99YXE507IL (Tenofovir)
      0 (Drugs, Essential)
      0 (RNA, Viral)
      G70B4ETF4S (Emtricitabine)
      0 (Anti-HIV Agents)
      0 (Drug Combinations)
    • Publication Date:
      Date Created: 20220926 Date Completed: 20221110 Latest Revision: 20221110
    • Publication Date:
      20231215
    • Accession Number:
      10.1080/14737167.2022.2117162
    • Accession Number:
      36154357